REG - RTW Biotech Opp. - Notice of AGM

RTW Biotech OpportunitiesAnnouncement

18/04/2024 09:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240418:nRSR1584La&default-theme=true

RNS Number : 1584L  RTW Biotech Opportunities Ltd  18 April 2024

LEI: 549300Q7EXQQH6KF7Z84

18 April 2024

RTW Biotech Opportunities Ltd
(the "Company")

Notice of Annual General Meeting

RTW Biotech Opportunities Ltd announces that its Annual General Meeting
("AGM") will be held at 1(st) Floor Royal Chambers, St Julian's Avenue St
Peter Port, Guernsey on 16 May 2024 at 2pm BST. The Notice of AGM was
dispatched to all shareholders on 17 April 2024.

A copy of the Notice of AGM has been submitted to the National Storage
Mechanism and will shortly be available for inspection
at https://data.fca.org.uk/#/nsm/nationalstoragemechanism
(https://data.fca.org.uk/#/nsm/nationalstoragemechanism) The Notice of AGM may
also be viewed on the Company's website
at www.rtwfunds.com/rtw-biotech-opportunities-ltd
(https://www.rtwfunds.com/rtw-biotech-opportunities-ltd/)

The Annual Report and Audited Financial Statements for the year ended 31
December 2023 (the "Annual Report") is also available on the Company's
website at www.rtwfunds.com/rtw-biotech-opportunities-ltd
(http://www.rtwfunds.com/rtw-biotech-opportunities-ltd)

You will not have received a hard copy proxy form for the AGM in the post. You
can instead submit your proxy vote electronically by accessing the shareholder
portal at www.signalshares.com, logging in and selecting the 'Vote Online Now'
link. Full details of how to vote are set out in the Notes to the Notice of
Meeting. Please submit your proxy vote so as to reach the Company's registrar
as soon as possible and in any event no later than 2pm BST on 14 May 2024 or,
if you are a CREST member, by using the service provided by Euroclear. Shares
held on your behalf by a broker or nominee must be voted by the broker, per
your instructions, and cannot be voted at www.signalshares.com. The completion
of the form of proxy will not preclude a member from attending and voting in
person at the meeting if it is so allowed.

If any shareholder has questions related to the business of the AGM, please
submit your queries to biotechopportunities@rtwfunds.com
(mailto:biotechopportunities@rtwfunds.com) by 2pm BST on 14 May 2024. We will
endeavour to answer every shareholder question and responses will be posted on
the Company's website after the AGM.

For Further Information

 RTW Investments, LP                                      +44 20 7959 6361
 Woody Stileman, Managing Director, Business Development  biotechopportunities@rtwfunds.com (mailto:biotechopportunities@rtwfunds.com)

 Krisha McCune, Director, Investor Relations

 Buchanan (PR & Communications Adviser)                   +44 20 7466 5107
 Charles Ryland
 Henry Wilson
 George Beale

 Deutsche Numis (Joint Corporate Broker)                  +44 20 7260 1000
 Freddie Barnfield
 Nathan Brown
 Euan Brown

 BofA Securities (Joint Corporate Broker)                 +44 20 7628 1000
 Edward Peel
 Alex Penney

 Cadarn Capital (Distribution & IR Partner)               +44 73 6888 3211
 David Harris

 Elysium Fund Management Limited                          +44 14 8181 0100

 Joanna Duquemin Nicolle, Chief Executive Officer

 Sadie Morrison, Managing Director

 Morgan Stanley Fund Services USA LLC                     +1 914 225 8885

 

About Biotech Opportunities Ltd:

RTW Biotech Opportunities Ltd (LSE: RTW & RTWG) is an investment fund
focused on identifying transformative assets with high growth potential across
the biopharmaceutical and medical technology sectors. Driven by a long-term
approach to support innovative businesses, RTW Biotech Opportunities Ltd
invests in companies developing next-generation therapies and technologies
that can significantly improve patients' lives. RTW Biotech Opportunities Ltd
is managed by RTW Investments, LP, a leading healthcare-focused
entrepreneurial investment firm with deep scientific expertise and a strong
track record of supporting companies developing life-changing therapies.

Visit the website at www.rtwfunds.com/rtw-biotech-opportunities-ltd
(https://www.rtwfunds.com/rtw-biotech-opportunities-ltd/)  for more
information.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOAEAXLPFDLLEEA